A pilot study of healing critical-sized calvarial defects by LL-37-generated monoosteophils.
Le. Keith K; Liu. Huinan H; Zhang. Chaoxing C; Li. Zhuo Z; Olafsen. Tove T; Fong. Yuman Y; Shively. John E JE; Zhang. Zhifang Z
Key Findings
- LL-37-treated monocytes become boneâforming monoosteophils
- Monoosteophils plus nanoâhydroxyapatite repaired 80% of criticalâsize skull defects in mice
- Even low numbers of monoosteophils (0.6âŻĂâŻ10â¶ cells) were effective and formed mineral granules inside the cells
Practical Outcomes
- This isnât a readyâtoâuse protocol for individuals, but it shows LL-37 has potential for future boneârepair therapies. Enthusiasts should watch for developments in cellâbased treatments or LL-37âderived supplements, though current applications require specialized lab work.
Summary
LL-37 can reprogram human blood monocytes into a new cell type called monoosteophils that can make bone, and when these cells are mixed with tiny hydroxyapatite particles they helped heal large skull bone holes in mice, but the method needs lab-grown cells and isnât something you can do at home yet.
Abstract
Monoosteophils, derived from LL-37-treated monocytes, are a novel type of calcifying/bone forming cells. We have shown that monoosteophils can form bone-like nodules <i>in vitro</i> and accelerate bone repair in a drilled femur defect model. Here, we explored the bone repair function of monoosteophils in a mouse model of critical-sized calvarial defect and the mechanism of bone nodule formation of monoosteophils <i>in vitro</i>. Human monocytes were isolated from peripheral blood and differentiated into monoosteophils. Critical-sized (5 mm-diameter) calvarial defects in the parietal bone of adult male NOD/SCID mice were implanted with either 1-day untreated human monocytes, 1-day LL-37 treated human monocytes (monoosteophils), 1-day human monocytes plus hydroxyapatite nanoparticles or 1-day human monoosteophils plus hydroxyapatite nanoparticles. Micro-computed tomography (µCT) was used for assessment of bone formation in the mouse model. Alizarin Red S staining (ARS), FAM-alendronate staining, light and fluorescence microscopy, scanning electron microscopy (SEM), energy dispersive X-ray spectroscopy (EDS) and transmitted electron microscopy (TEM) were used to examine bone nodule formation <i>in vitro</i>. The most complete healing (80%) was observed for monoosteophils plus nano-scale hydroxyapatite. The results of a dose response study (5 × 10<sup>6</sup>, 2.5 × 10<sup>6</sup>, 1.25 × 10<sup>6</sup> and 0.625 × 10<sup>6</sup> MOP cells) showed that monoosteophil cell counts as low as 0.625 × 10<sup>6</sup> cells were able to significantly repair the defect area over a short-term observation period of 4 weeks. Mechanistic <i>in vitro</i> studies using ARS and FAM-alendronate staining showed that monoosteophils form bone nodule in αMEM medium supplemented with 2.5 mM CaCl<sub>2</sub>. SEM/EDS analysis confirmed that the bone nodules consisted of phosphorus, calcium, oxygen, and sodium. Monoosteophils in culturing condition formed the unique granules in the cytoplasm consisting of phosphorus, calcium, oxygen, and sodium evidenced by SEM/EDS. We now demonstrate that the bone repair function of monoosteophils requires hydroxyapatite through intracellular nodule formation and monoosteophils are capable of filling in large calvarial defects in our pilot study. These observations may have important implications in facilitating the development of therapeutic applications for clinically challenging bone repairs and the understanding of pathological mineralization.
Study Information
pubmed
2025
2025-07-14T00:00:00.000Z
10.3389/fbioe.2025.1583496
52